Engineered prostate-specific membrane antigen-targeted liposomal nanoplatform integrating near-infrared fluorescence, ultrasound, and magnetic resonance imaging for precision prostate cancer imaging

Le résumé fourni par la source

• PSMA-targeted liposomes co-loaded with ICG, PFP, and MnO 2 enable tri-modal imaging. • Tailored liposomal architecture synchronizes NIR fluorescence, US, and MRI signals. • Engineered surface boosts PSMA-specific tumor targeting and cellular internalization. • Tri-modal imaging demonstrates 4.6 × NIR and 3.2 × US enhancement in PSMA + tumors. • Liposomal nanoplatform exhibits strong translational potential for image-guided diagnosis. Accurate and early diagnosis of prostate cancer remains clinically challenging due to the limitations of single-modality imaging. A prostate-specific membrane antigen (PSMA)-functionalized tri-modal liposomal nanoplatform was developed by co-loading indocyanine green (ICG), perfluoropentane (PFP), and manganese dioxide (MnO 2 ) to enable near-infrared fluorescence (NIR), ultrasonography (US), and magnetic resonance imaging (MRI). Anti-PSMA antibodies were electrostatically adsorbed onto the liposomal surface to provide PSMA-directed targeting potential. In vitro, PFP/ICG/Lip/MnO 2 @PSMA + showed enhanced NIR fluorescence compared with free ICG at matched concentrations, achieved > 3.5-fold higher US contrast with increasing PFP volume fraction, and showed a linear correlation between R 1 (1/T 1 ) and Mn concentration. PSMA-positive LNCaP cells showed 3.6-fold higher uptake than non-targeted liposomes. In vivo studies revealed biphasic blood clearance based on Mn quantification (elimination half-life, 4.29 h) and progressive tumor enrichment, with the highest tumor Mn uptake (∼8.7% ID/g) observed at 8 h post-injection. Consistently, they generated stronger NIR fluorescence, US contrast, and T 1 -weighted MRI signals in LNCaP xenografts. Histology and serum biochemistry revealed no detectable systemic toxicity.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.